UNSPSC 51263014: Trimazosin hydrochloride

This classification denotes the hydrochloride form of an alpha-adrenergic blocking agent with the molecular formula C20H29N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31L760807H, chemically known as 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylic acid, 2-hydroxy-2-methylpropyl ester but more generally known as trimazosin, which bears US NIH Compound Identifier 37264. European Medicines Agency schedules Trimazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11298MIG.

UNSPSC 51263014 Trimazosin hydrochloride is a Commodity code for a specific pharmaceutical product, but recent state and local opportunities tagged under this code show little relevant activity — the two posted solicitations address naloxone and drug deactivation systems (Seminole County, Florida) and a direct-to-manufacturer pharmacy program (Texas Health and Human Services Commission), neither of which involves trimazosin hydrochloride procurement. The code nominally covers a single active pharmaceutical ingredient used in antihypertensive therapy, yet the recent opportunities reflect broader pharmaceutical supply and pharmacy benefit management initiatives rather than the narrow product scope the code name indicates. This mismatch suggests either miscoding of the opportunities or limited recent demand for trimazosin specifically under state and local procurement channels.

The two opportunities that carry this code tag represent different procurement models and issuing bodies. Seminole County, Florida posted an IFB (Solicitation Number IFB60459723LAS) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements. Activity appears concentrated in Florida and Texas, with issuing bodies spanning county health departments and state health agencies, but the opportunities do not establish active demand for trimazosin hydrochloride itself under this code.